COMMUNIQUÉS West-GlobeNewswire

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
09/03/2026
Lyon (France), March 9 , 202 6 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The [...]
GENFIT reçoit la désignation Orphan Drug de la FDA pour NTZ dans le traitement de l’ACLF
09/03/2026
La FDA accorde la désignation Orphan Drug (ODD) à NTZ dans l'ACLF, syndrome grave pour lequel il n'existe aucun traitement approuvé NTZ est développé dans l'ACLF via sa nouvelle formulation G1090N, conçue pour optimiser [...]
Radiant Health Centers Announces Honorees for 40th Annual Gala Celebrating Four Decades of Compassionate Care
09/03/2026
Jai Rodriguez and Harper Steele Headline Evening Honoring Cultural Impact, Legacy Leadership, and Community Hope Irvine, CA, March 09, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers , Orange County’s largest provider [...]
EssilorLuxottica: Disclosure of transactions in own shares
09/03/2026
Disclosure of transactions in own shares Paris, France (March 9, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that from [...]
Glaucoma Research Foundation and Alcon Partner to Expand Access to Trusted Glaucoma Education
09/03/2026
New English and Spanish editions of Understanding and Living with Glaucoma and first-ever Spanish audiobook aim to reach high-risk Hispanic communities Resources will be available during Glaucoma Awareness Week [...]
Surgery Partners, Inc. to Present at Upcoming Investor Conference
09/03/2026
BRENTWOOD, Tenn., March 09, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), is scheduled to meet with investors at the Barclays 28 th Annual Global Healthcare [...]
Transactions in Connection with Share Buy-back Program
09/03/2026
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum [...]
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
09/03/2026
FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapies NTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical potential for [...]
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 In the fourth paragraph, we are replacing milligrams with micrograms . The corrected press release follows. CARMEL, Ind., March 09, [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
09/03/2026
Déclaration de transactions sur actions propres Paris, France (9 mars 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que du 2 mars 2026 au 4 [...]
Valneva publiera ses résultats financiers consolidés 2025 le 18 mars 2026
09/03/2026
Lyon (France), le 9 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA, société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers pour l’exercice 2025 le mercredi 18 [...]
Hydration Room Opens in San Francisco’s Cow Hollow, Introducing Nurse-Administered, Medically Supervised IV Therapy Designed for Sustained Performance and Recovery
09/03/2026
New Union Street clinic delivers personalized hydration, immunity and performance support designed for sustained energy and resilience SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Hydration Room , a leading [...]
Zealand Pharma to participate in upcoming investor conferences in March 2026
09/03/2026
Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology [...]
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company [...]
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
09/03/2026
97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating [...]
Route 92 Medical Enrolls First Patient in SUMMIT RISE Study
09/03/2026
SUMMIT RISE is expected to enroll up to 500 patients to evaluate the performance of Route 92 Medical’s neurovascular intervention device portfolio WEST JORDAN, Utah, March 09, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, [...]
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
09/03/2026
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
09/03/2026
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late- [...]
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
09/03/2026
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Pages